Compare Stocks: GNTA, ENGN, PMN, and ANIX

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ANIX Anixa Biosciences	$3.25 +0.9%	$3.06	$2.32 ▼ $5.46	$110.58M	0.55	177,729 shs	88,517 shs
ENGN enGene	$1.74 -4.4%	$1.78	$1.40 ▼ $12.25	$116.55M	-0.28	1.04 million shs	907,282 shs
GNTA Genenta Science	$1.30	$1.63	$0.55 ▼ $10.00	$30.67M	0.77	1.04 million shs	14,669 shs
PMN Promis Neurosciences	$14.68 -1.9%	$12.44	$6.27 ▼ $27.40	$131.68M	-0.23	111,339 shs	6,614 shs

7 Stocks to Buy And Hold Forever

Click the link to see MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ANIX Anixa Biosciences	-0.92%	-5.57%	+5.23%	+11.03%	+9.52%
ENGN enGene	+4.00%	+1.68%	-4.21%	+18.18%	-50.68%
GNTA Genenta Science	0.00%	+2.36%	-13.33%	+121.54%	-63.22%
PMN Promis Neurosciences	+1.70%	+10.32%	+5.05%	+41.63%	-4.65%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ANIX Anixa Biosciences	$3.25 +0.9%	$3.06	$2.32 ▼ $5.46	$110.58M	0.55	177,729 shs	88,517 shs
ENGN enGene	$1.74 -4.4%	$1.78	$1.40 ▼ $12.25	$116.55M	-0.28	1.04 million shs	907,282 shs
GNTA Genenta Science	$1.30	$1.63	$0.55 ▼ $10.00	$30.67M	0.77	1.04 million shs	14,669 shs
PMN Promis Neurosciences	$14.68 -1.9%	$12.44	$6.27 ▼ $27.40	$131.68M	-0.23	111,339 shs	6,614 shs

7 Stocks to Buy And Hold Forever

Click the link to see MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ANIX Anixa Biosciences	-0.92%	-5.57%	+5.23%	+11.03%	+9.52%
ENGN enGene	+4.00%	+1.68%	-4.21%	+18.18%	-50.68%
GNTA Genenta Science	0.00%	+2.36%	-13.33%	+121.54%	-63.22%
PMN Promis Neurosciences	+1.70%	+10.32%	+5.05%	+41.63%	-4.65%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ANIX Anixa Biosciences	2.80	Moderate Buy	$8.50	163.98% Upside
ENGN enGene	2.14	Hold	$11.05	506.89% Upside
GNTA Genenta Science	1.00	Sell	N/A	N/A
PMN Promis Neurosciences	2.88	Moderate Buy	$31.50	110.42% Upside

Current Analyst Ratings Breakdown

Latest GNTA, ENGN, PMN, and ANIX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/30/2026	GNTA Genenta Science	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
7/28/2026	PMN Promis Neurosciences	Guggenheim Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$35.00 ➝ $69.00
7/27/2026	PMN Promis Neurosciences	Chardan Capital Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target	Buy	$20.00
7/27/2026	PMN Promis Neurosciences	Chardan Capital Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy	$20.00
7/21/2026	ANIX Anixa Biosciences	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Hold ➝ Strong-Buy
7/15/2026	PMN Promis Neurosciences	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
7/10/2026	GNTA Genenta Science	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
7/7/2026	PMN Promis Neurosciences	Roth Capital Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy	$19.00
7/7/2026	PMN Promis Neurosciences	Roth Capital Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Strong-Buy
6/30/2026	PMN Promis Neurosciences	Cantor Fitzgerald Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Overweight
6/30/2026	ANIX Anixa Biosciences	D. Boral Capital Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$10.00

(Data available from 8/12/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ANIX Anixa Biosciences	N/A	N/A	N/A	N/A	$0.42 per share	N/A
ENGN enGene	N/A	N/A	N/A	N/A	$2.60 per share	N/A
GNTA Genenta Science	N/A	N/A	N/A	N/A	$1.29 per share	N/A
PMN Promis Neurosciences	N/A	N/A	N/A	N/A	($0.58) per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ANIX Anixa Biosciences	-$10.93M	-$0.31	N/A	N/A	N/A	N/A	-71.12%	-62.88%	9/10/2026 (Estimated)
ENGN enGene	-$117.30M	-$2.17	N/A	N/A	N/A	N/A	-56.06%	-45.64%	9/14/2026 (Estimated)
GNTA Genenta Science	-$7.39M	N/A	N/A	N/A	N/A	N/A	N/A	N/A	9/2/2026 (Estimated)
PMN Promis Neurosciences	-$39.72M	-$14.51	N/A	N/A	N/A	N/A	-237.99%	-151.04%	8/13/2026 (Estimated)

Latest GNTA, ENGN, PMN, and ANIX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
9/2/2026	N/A	GNTA Genenta Science	-$0.2741	N/A	N/A	N/A	N/A	N/A
8/13/2026	Q2 2026	PMN Promis Neurosciences	-$1.3786	N/A	N/A	N/A	N/A	N/A
6/15/2026	Q2 2026	ENGN enGene	-$0.48	-$0.43	+$0.05	-$0.43	N/A	N/A
6/10/2026	Q2 2026	ANIX Anixa Biosciences	-$0.10	-$0.07	+$0.03	-$0.07	N/A	N/A
5/12/2026	Q1 2026	PMN Promis Neurosciences	-$1.06	-$1.26	-$0.20	-$1.26	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
ANIX Anixa Biosciences	N/A	N/A	N/A	N/A	N/A
ENGN enGene	$1.58	86.87%	N/A	N/A	N/A
GNTA Genenta Science	N/A	N/A	N/A	N/A	N/A
PMN Promis Neurosciences	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ANIX Anixa Biosciences	N/A	9.79	9.79
ENGN enGene	0.10	12.57	12.57
GNTA Genenta Science	0.35	14.16	14.16
PMN Promis Neurosciences	N/A	9.92	9.92

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ANIX Anixa Biosciences	29.13%
ENGN enGene	64.16%
GNTA Genenta Science	15.13%
PMN Promis Neurosciences	50.13%

Insider Ownership

Company	Insider Ownership
ANIX Anixa Biosciences	26.40%
ENGN enGene	10.50%
GNTA Genenta Science	28.99%
PMN Promis Neurosciences	1.50%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ANIX Anixa Biosciences	5	34.02 million	25.04 million	Optionable
ENGN enGene	31	66.99 million	59.95 million	N/A
GNTA Genenta Science	7	23.59 million	16.75 million	Not Optionable
PMN Promis Neurosciences	5	8.97 million	8.83 million	Not Optionable

GNTA, ENGN, PMN, and ANIX Headlines

Recent News About These Companies

Promis Neurosciences (NASDAQ:PMN) Receives Consensus Rating of "Moderate Buy" from Analysts

August 7, 2026 | marketbeat.com

Promis Neurosciences (PMN) to Release Quarterly Earnings on Thursday

August 6, 2026 | americanbankingnews.com

Promis Neurosciences (PMN) Projected to Post Earnings on Thursday

August 6, 2026 | marketbeat.com

Janus Henderson Group PLC Acquires New Position in Promis Neurosciences $PMN

August 4, 2026 | marketbeat.com

Vertex Pharmaceuticals Inc (VRTX) (Q2 2026) Earnings Call Highlights: Revenue Surges 12% to $3.3 Billion, Driven by CF Portfolio and New Product Momentum

August 4, 2026 | gurufocus.com

ProMIS Neurosciences to Report Second Quarter 2026 Financial Results and Business Update on August 13, 2026

August 3, 2026 | globenewswire.com

ADAR1 Capital Management LLC Buys Shares of 95,350 Promis Neurosciences $PMN

July 30, 2026 | marketbeat.com

Promis Neurosciences (NASDAQ:PMN) Upgraded at Chardan Capital

July 29, 2026 | marketbeat.com

Yu Fan Buys New Stake in Promis Neurosciences $PMN

July 29, 2026 | marketbeat.com

Promis Neurosciences $PMN Stock Holdings Boosted by Ally Bridge Group NY LLC

July 29, 2026 | marketbeat.com

Promis Reports No ARIA-E in PMN310 Alzheimer’s Trial Interim Data

July 28, 2026 | marketbeat.com

Small-Cap ProMIS Neurosciences Says Lead Drug Shows Encouraging Action in Early Alzheimer's Study

July 28, 2026 | benzinga.com

ProMIS Neurosciences Reports Positive Blinded Six-Month Interim Safety and Biomarker Data for PMN310 in the PRECISE-AD Phase 1b Alzheimer’s Disease Trial

July 28, 2026 | markets.businessinsider.com

ProMIS Neurosciences Reports Positive Blinded Six-Month Interim Safety and Biomarker Data for PMN310 in the PRECISE-AD Phase 1b Alzheimer's Disease Trial

July 28, 2026 | globenewswire.com

ProMIS Neurosciences Inc.: ProMIS Neurosciences to Host Webinar to Discuss Upcoming 6-Month Blinded Interim Data from PRECISE-AD Phase 1b Trial of PMN310 in Alzheimer's Disease

July 27, 2026 | finanznachrichten.de

ProMIS Neurosciences to Host Webinar to Discuss Upcoming 6-Month Blinded Interim Data from PRECISE-AD Phase 1b Trial of PMN310 in Alzheimer’s Disease

July 27, 2026 | markets.businessinsider.com

ProMIS Neurosciences to Host Webinar to Discuss Upcoming 6-Month Blinded Interim Data from PRECISE-AD Phase 1b Trial of PMN310 in Alzheimer's Disease

July 27, 2026 | globenewswire.com

Promis Neurosciences (NASDAQ:PMN) Upgraded to "Sell" at Wall Street Zen

July 18, 2026 | marketbeat.com

PMN310 cuts Alzheimer oligomers in humans, dodging side effects that limit rival drugs

July 15, 2026 | msn.com

ProMIS Neurosciences Reports First Human Evidence of Amyloid-Beta Oligomer Target Engagement by PMN310 at AAIC 2026

July 14, 2026 | globenewswire.com

Promis Neurosciences (NASDAQ:PMN) Given Average Rating of "Moderate Buy" by Brokerages

July 13, 2026 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

GNTA, ENGN, PMN, and ANIX Company Descriptions

Anixa Biosciences NASDAQ:ANIX

$3.25 +0.03 (+0.93%)

As of 01:28 PM Eastern

Anixa Biosciences, Inc., a biotechnology company, develops therapies and vaccines focusing on critical unmet needs in oncology and infectious diseases. The company's therapeutics programs include the development of a chimeric endocrine receptor T-cell therapy, a novel form of chimeric antigen receptor T-cell (CAR-T) technology focusing on the treatment of ovarian cancer. Its vaccine programs comprise the development of a vaccine against triple negative breast cancer; and a preventative vaccine against ovarian cancer. The company is also developing immuno-therapy drugs against cancer. The company was formerly known as ITUS Corporation and changed its name to Anixa Biosciences, Inc. in October 2018. Anixa Biosciences, Inc. was incorporated in 1982 and is based in San Jose, California.

enGene NASDAQ:ENGN

$1.74 -0.08 (-4.40%)

As of 01:28 PM Eastern

enGene Holdings Inc., through its subsidiary enGene, Inc., operates as a clinical-stage biotechnology company that develops genetic medicines through the delivery of therapeutics to mucosal tissues and other organs. Its lead product candidate is EG-70 (detalimogene voraplasmid), which is a non-viral immunotherapy to treat non-muscle invasive bladder cancer patients with carcinoma-in-situ (Cis), who are unresponsive to treatment with Bacillus Calmette-Guérin. The company was founded in 2023 and is based in Saint-Laurent, Canada.

Genenta Science NASDAQ:GNTA

$1.30 0.00 (0.00%)

As of 12:35 PM Eastern

Genenta Science S.p.A., a clinical-stage biotechnology company, engages in the development of hematopoietic stem cell gene therapies for the treatment of solid tumors in Italy. Its lead product candidate is Temferon, which is in Phase 1/2a clinical trials for use in the treatment of glioblastoma multiforme in patients with unmethylated MGMT gene promoter. The company is developing Temferon for use in the treatment of other solid tumor indications, locally advanced hepatocellular carcinoma, and intra-hepatic cholangiocarcinoma. In addition, it develops biologic platform to deliver immunomodulatory molecules directly to the tumor by infiltrating monocytes/macrophages. Genenta Science S.p.A. was incorporated in 2014 and is headquartered in Milan, Italy.

Promis Neurosciences NASDAQ:PMN

$14.68 -0.29 (-1.94%)

As of 12:52 PM Eastern

ProMIS Neurosciences, Inc. discovers and develops antibody therapies and therapeutic vaccines neurodegenerative diseases and other misfolded protein diseases in Canada. The company's proprietary discovery platform comprises ProMIS and Collective Coordinates algorithms to predict novel targets known as disease specific epitopes on the molecular surface of misfolded proteins. Its lead product candidates comprise of PMN310, a monoclonal antibody (mAb) for toxic oligomers in AD; PMN267, a TDP-43; and PMN442, a mAb targeting toxic a-syn oligomers and seeding fibrils. The company was formerly known as Amorfix Life Sciences Ltd. and changed its name to ProMIS Neurosciences, Inc. in July 2015. ProMIS Neurosciences, Inc. was incorporated in 2004 and is headquartered in Toronto, Canada.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest GNTA, ENGN, PMN, and ANIX Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest GNTA, ENGN, PMN, and ANIX Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

GNTA, ENGN, PMN, and ANIX Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

GNTA, ENGN, PMN, and ANIX Company Descriptions

Anixa Biosciences NASDAQ:ANIX

enGene NASDAQ:ENGN

Genenta Science NASDAQ:GNTA

Promis Neurosciences NASDAQ:PMN

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest GNTA, ENGN, PMN, and ANIX Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest GNTA, ENGN, PMN, and ANIX Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

GNTA, ENGN, PMN, and ANIX Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

GNTA, ENGN, PMN, and ANIX Company Descriptions

Anixa Biosciences NASDAQ:ANIX

enGene NASDAQ:ENGN

Genenta Science NASDAQ:GNTA

Promis Neurosciences NASDAQ:PMN

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools